Shumin Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10266778/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	High Mobility Group Protein B1 Decreases Surface Localization of PD-1 to Augment T-cell Activation. Cancer Immunology Research, 2022, 10, 844-855.	3.4	4
2	Peripheral blood hsa-circRNA5333-4: A novel biomarker for myasthenia gravis. Clinical Immunology, 2021, 224, 108676.	3.2	2
3	No correlation between acetylcholine receptor antibody concentration and individual clinical symptoms of myasthenia gravis: A systematic retrospective study involving 67 patients. Brain and Behavior, 2021, 11, e02203.	2.2	9
4	Targeting CD276 by CAR-T cells induces regression of esophagus squamous cell carcinoma in xenograft mouse models. Translational Oncology, 2021, 14, 101138.	3.7	14
5	Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma. Cancer Letters, 2021, 518, 35-48.	7.2	76
6	Antibodies to Full-Length Agrin Protein in Chinese Patients With Myasthenia Gravis. Frontiers in Immunology, 2021, 12, 753247.	4.8	4
7	HMGB1 in inflammation and cancer. Journal of Hematology and Oncology, 2020, 13, 116.	17.0	117
8	PD-1 abrogates the prolonged persistence of CD8+ CAR-T cells with 4-1BB co-stimulation. Signal Transduction and Targeted Therapy, 2020, 5, 164.	17.1	9
9	A novel MuSK cell-based myasthenia gravis diagnostic assay. Journal of Neuroimmunology, 2019, 337, 577076.	2.3	8
10	Cancer-cell-secreted CXCL11 promoted CD8+ T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC. , 2019, 7, 42.		122
11	Targeting glycosylation of PD-1 to enhance CAR-T cell cytotoxicity. Journal of Hematology and Oncology, 2019, 12, 127.	17.0	44
12	A cycle involving HMGB1, IFN-Î ³ and dendritic cells plays a putative role in anti-tumor immunity. Cellular Immunology, 2019, 343, 103850.	3.0	17